electroCore (ECOR) investor relations material

Business performance and growth

• Achieved a five-year CAGR of approximately 50% and expanded gross margins from 72% in 2019 to 87% in Q1 2026.

• Q1 2026 revenue reached $9.6 million, with $8.8 million in cash; full-year 2026 revenue is guided to $42 million, targeting 30%+ annual growth.

• Revenue growth is driven by new patient starts, robust refill pipeline, and a bifurcated sales model using both employees and commission-based reps.

• Focus on improving operating leverage and reducing sales and marketing expenses from 60% to 40% of revenue.

• Clean cap table with no variable rate securities or dilution from recent acquisitions.

Product portfolio and innovation

• Main products include gammaCore (prescription, non-invasive vagus nerve stimulator for headaches), Quell (fibromyalgia), and Truvaga (consumer wellness).

• gammaCore is FDA-cleared and primarily adopted by the VA for headache treatment, generating about $25 million in revenue.

• Quell, acquired in 2025, rapidly grew from $50,000/month to over $1 million in Q1 2026, targeting fibromyalgia in military populations.

• Truvaga targets the large consumer wellness market, with plans to introduce subscription models for recurring revenue.

• TAC-STIM, developed with the Air Force, is used for cognitive performance and sleep improvement in military settings.

Market expansion and commercial strategy

• New COO Mike Fox, with a decade of federal market experience, is leading commercial expansion and sales optimization.

• VA remains the largest channel, but only 2.5% of 600,000 headache patients have been reached, indicating significant upside.

• Commercial adoption is expanding through contracts with Kaiser Permanente and targeting other federal programs like TRICARE and Federal Workers Comp.

• Territory realignment and increased sales presence aim to deepen penetration in under-served VA facilities.

• Platform technology enables ongoing investigator-initiated trials in areas like PTSD, long COVID, and stroke.